Pfizer to present Phase 3 SigVie-002 survival data at ESMO 2026

Pfizer said it will present late-breaking Phase 3 survival results for sigvotatug vedotin in previously treated non-squamous NSCLC on Oct. 25, 2026, alongside other oncology data at ESMO 2026 in Madrid.